Biotech drug developer Human Genome Sciences Inc. has rejected an unsolicited $2.59 billion takeover offer from GlaxoSmithKline PLC, saying it undervalues the company.
But the Rockville, Md., company said Thursday that it has decided to explore its strategic options, which could include a potential sale of the company. It invited GlaxoSmithKline to participate in its exploratory process.
{iframe}http://www.washingtonpost.com/business/industries/human-genome-sciences-rejects-259b-bid-from-glaxosmithkline-but-is-exploring-options/2012/04/19/gIQAkv5pST_story.html{/iframe}